Differential diagnosis of longitudinally extensive transverse myelitis in adults

European Neurological Journal

Volumn 3, Issue 1, 2011, Pages 27-39

  Eckstein, Christopher ^a   Syc, Stephanie ^a   Saidha, Shiv ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Longitudinally extensive transverse myelitis (LETM); Myelopathy; Neuromyelitis optica (NMO)

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIGOCLONAL BAND; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTERIOVENOUS SHUNT; BEHCET DISEASE; BRAIN VASCULITIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIATION INJURY; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SPINAL CORD ISCHEMIA; SPINAL CORD TUMOR; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 80655142683     PISSN: 20418000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002; 59:499-505.
2. Scott TF, Kassab SL, Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler. 2005;11:373-377.
3. Scott TF, Bhagavatula K, Snyder PJ, Chieffe C. Transverse myelitis. Comparison with spinal cord presentations of multiple sclerosis. Neurology. 1998;50:429-433.
4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-1489.
5. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60: 848-853.
6. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68:603-605.
7. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol. 2008;255:163-170.
8. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390-396.
9. Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler. 2004;10:2-4.
10. Zaffaroni M. Cerebrospinal fluid findings in Devic's neuromyelitis optica. Neurol Sci. 2004;25(Suppl. 4):S368-S370.
11. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgGmarker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-477.
12. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-2112.
13. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13: 256-259.
14. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci. 2007;28:209-211.
15. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270-1272.
16. Matsuoka T, Matsushita T, Osoegawa M, et al. Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. J Neurol Sci. 2008;266:115-125.
17. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003;2:117-127.
18. Chong HT, Ramli N, Lee KH, et al. Magnetic resonance imaging of Asians with multiple sclerosis was similar to that of the West. Can J Neurol Sci. 2006;33:95-100.
19. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62:226-233.
20. Qiu W, Wu JS, Zhang MN, et al. Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database. J Neurol Neurosurg Psychiatry. 2010;81:209-212.
21. Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology. 1995;195:725-732.
22. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
23. Kim SM, Waters P, Vincent A, et al. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler. 2009;15:1062-1068.
24. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280-291.
25. Pericot I, Brieva L, Tintore M, et al. Myelopathy in seronegative Sjogren syndrome and/or primary progressive multiple sclerosis. Mult Scler. 2003;9:256-259.
26. Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE. Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med. 1986;104:323-330.
27. Williams CS, Butler E, Roman GC. Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol. 2001;58:815-819.
28. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120-124.
29. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:985-992.
30. Warren RW, Kredich DW. Transverse myelitis and acute central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum. 1984;27:1058-1060.
31. Deodhar AA, Hochenedel T, Bennett RM. Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis. J Rheumatol. 1999;26:446-449.
32. Chan KF, Boey ML. Transverse myelopathy in SLE: clinical features and functional outcomes. Lupus. 1996;5:294-299.
33. Rheu CW, Lee SI, Yoo WH. A catastrophic-onset longitudinal myelitis accompanied by bilateral internuclear ophthalmoplegia in a patient with systemic lupus erythematosus. J Korean Med Sci. 2005;20:1085-1088.
34. Espinosa G, Mendizabal A, Minguez S, et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum. 2010;39:246-256.
35. Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol. 1990;17:34-37.
36. Sherer Y, Hassin S, Shoenfeld Y, et al. Transverse myelitis in patients with antiphospholipid antibodies-the importance of early diagnosis and treatment. Clin Rheumatol. 2002;21:207-210.
37. Propper DJ, Bucknall RC. Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis. 1989;48:512-515.
38. Boumpas DT, Patronas NJ, Dalakas MC, Hakim CA, Klippel JH, Balow JE. Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol. 1990;17: 89-92.
39. Salmaggi A, Lamperti E, Eoli M, et al. Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clin Exp Rheumatol. 1994;12:389-394.
40. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus-the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol. 1992;19:370-372.
41. Armstrong DJ, McCarron MT, Wright GD. SLE-associated transverse myelitis successfully treatedwith Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int. 2006;26:771-772.
42. D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004;31:280-285.
43. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335:1078-1080.
44. Yazici H, Yurdakul S, Hamuryudan V. Behcet disease. Curr Opin Rheumatol. 2001;13:18-22.
45. Siva A, Altintas A, Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol. 2004;17:347-357.
46. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro- Behcet Study Group. Brain. 1999;122(Pt. 11):2171-2182.
47. Serdaroglu P. Behcet's disease and the nervous system. J Neurol. 1998;245:197-205.
48. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behcet's syndrome. Brain. 1999;122(Pt. 11):2183-2194.
49. Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P. Cytokines and chemokines in neuro-Behcet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145:127-134.
50. Siva A, Kantarci OH, Saip S, et al. Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248: 95-103.
51. Kocer N, Islak C, Siva A, et al. CNS involvement in neuro-Behcet syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20:1015-1024.
52. Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G. Clinical characteristics and course of spinal cord involvement in Behcet's disease. Eur J Neurol. 2007;14:729-737.
53. Kidd D, Beynon HL. The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:85-94.
54. Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci. 2008;272:99-105.
55. Siva A, Fresko II. Behcet's Disease. Curr Treat Options Neurol. 2000;2: 435-448.
56. Chapelon-Abric C. [Neurosarcoidosis]. Ann Med Interne (Paris). 2001; 152:113-124.
57. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. Amorphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167-172.
58. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42:909-917.
59. Cohen-Aubart F, Galanaud D, Grabli D, et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a casecontrol study. Medicine (Baltimore). 2010;89:133-140.
60. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160: 736-755
61. Dale JC, O'Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74:535.
62. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60-66.
63. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol. 2003;148:147-148.
64. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124:2023-2026.
65. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med. 2004;117:277-279.
66. Duna GF, Calabrese LH. Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol. 1995;22:662-667.
67. Salvarani C, Brown RD, Jr, Calamia KT, et al. Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford). 2008;47:1671-1677.
68. Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system. Arthritis Rheum. 1997;40:1189-1201.
69. Salvarani C, Brown RD, Jr, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 2007;62:442-451.
70. Benseler S, Schneider R. Central nervous system vasculitis in children. Curr Opin Rheumatol. 2004;16:43-50.
71. Lie JT. Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol. 1992;23:164-171.
72. Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR Am J Neuroradiol. 1999;20:75-85.
73. Harris KG, Tran DD, Sickels WJ, Cornell SH, Yuh WT. Diagnosing intracranial vasculitis: the roles of MR and angiography. AJNR Am J Neuroradiol. 1994;15:317-330.
74. Calabrese LH. Clinical management issues in vasculitis. Angiographically defined angiitis of the central nervous system: diagnostic and therapeutic dilemmas. Clin Exp Rheumatol. 2003;21:S127-S130.
75. Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA. Idiopathic granulomatous angiitis of the central nervous system. Diagnostic challenges. Arch Neurol. 1993;50:925-930.
76. Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol. 2009;66:704-709.
77. Levy JA, Shimabukuro J, Hollander H, Mills J, Kaminsky L. Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet. 1985;2:586-588.
78. Dal Pan GJ, Glass JD, McArthur JC. Clinicopathologic correlations of HIV- 1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology. 1994;44:2159-2164.
79. Petito CK. Review of central nervous system pathology in human immunodeficiency virus infection. Ann Neurol. 1988;23(Suppl):S54-S57.
80. Di Rocco A, Simpson DM. AIDS-associated vacuolar myelopathy. AIDS Patient Care STDS. 1998;12:457-461.
81. Berger JR, Sabet A. Infectious myelopathies. Semin Neurol. 2002;22: 133-142.
82. Chong J, Di Rocco A, Tagliati M, Danisi F, Simpson DM, Atlas SW. MR findings in AIDS-associated myelopathy. AJNR Am J Neuroradiol. 1999;20:1412-1416.
83. Santosh CG, Bell JE, Best JJ. Spinal tract pathology in AIDS: postmortem MRI correlation with neuropathology. Neuroradiology. 1995;37:134-138.
84. Lee HH, Weiss SH, Brown LS, et al. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle Atlantic and central regions of the USA. J Infect Dis. 1990;162:347-352.
85. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet. 1999;353:1951-1958.
86. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058-6068.
87. Taylor GP, Bodeus M, Courtois F, et al. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr. 2005;38:104-109.
88. Olindo S, Cabre P, Lezin A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol. 2006;63:1560-1566.
89. Araujo A, Lima MA, Silva MT. Human T-lymphotropic virus 1 neurologic disease. Curr Treat Options Neurol. 2008;10:193-200.
90. Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266-281.
91. Cooper S, van der Loeff MS, McConkey S, et al. Neurological morbidity among human T-lymphotropic-virus-type-1-infected individuals in a rural West African population. J Neurol Neurosurg Psychiatry. 2009;80: 66-68.
92. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586-593.
93. Araujo A, Hall WW. Human T-lymphotropic virus type II and neurological disease. Ann Neurol. 2004;56:10-19.
94. Nakamura M, Kuroki M, Kira J, et al. Elevated antibodies to synthetic peptides of HTLV-1 envelope transmembrane glycoproteins in patients with HAM/TSP. J Neuroimmunol. 1991;35:167-177.
95. Vernant JC, Maurs L, Gessain A, et al. Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. Ann Neurol. 1987;21:123-130.
96. Cabre P, Smadja D, Cabie A, Newton CR. HTLV-1 and HIV infections of the central nervous system in tropical areas. J Neurol Neurosurg Psychiatry. 2000;68:550-557.
97. Umehara F, Nose H, Saito M, et al. Abnormalities of spinalmagnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy. J Neurovirol. 2007;13:260-267.
98. Bagnato F, Butman JA, Mora CA, et al. Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol. 2005;11:525-534.
99. Croda MG, de Oliveira AC, Vergara MP, et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. J Neurol Sci. 2008;269:133-137.
100. Arimura K, Nakagawa M, Izumo S, et al. Safety and efficacy of interferonalpha in 167 patients with human T-cell lymphotropic virus type 1- associated myelopathy. J Neurovirol. 2007;13:364-372.
101. Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLVIassociated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology. 1996;46:1016-1021.
102. Matsuo H, Nakamura T, Tsujihata M, et al. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet. 1988;2:1109-1113.
103. Kikuchi S, Shinpo K, Niino M, Tashiro K. Subacute syphilitic meningomyelitis with characteristic spinal MRI findings. J Neurol. 2003;250:106-107.
104. Chilver-Stainer L, Fischer U, Hauf M, Fux CA, Sturzenegger M. Syphilitic myelitis: rare, nonspecific, but treatable. Neurology. 2009;72:673-675.
105. Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189:369-376.
106. Syphilis-CDC recommended treatment schedules, 1976. J Ark Med Soc. 1976;73:175-178.
107. Berger JR, McCarthy M. Neurosyphilis in patients infected with human immunodeficiency virus. Ann Neurol. 1990;27:213.
108. Saleem S, Belal AI, el-Ghandour NM. Spinal cord schistosomiasis: MR imaging appearance with surgical and pathologic correlation. AJNR Am J Neuroradiol. 2005;26:1646-1654.
109. Sandson TA, Friedman JH. Spinal cord infarction. Report of 8 cases and review of the literature. Medicine (Baltimore). 1989;68:282-292.
110. Novy J, Carruzzo A, Maeder P, Bogousslavsky J. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol. 2006;63:1113-1120.
111. Garland H, Greenberg J, Harriman DG. Infarction of the spinal cord. Brain. 1966;89:645-662.
112. Weidauer S, Nichtweiss M, Lanfermann H, Zanella FE. Spinal cord infarction: MR imaging and clinical features in 16 cases. Neuroradiology. 2002;44:851-857.
113. Luo CB, Chang FC, Teng MM, Chen SS, Lirng JF, Chang CY. Magnetic resonance imaging as a guide in the diagnosis and follow-up of spinal cord infarction. J Chin Med Assoc. 2003;66:89-95.
114. Loher TJ, Bassetti CL, Lovblad KO, et al. Diffusion-weighted MRI in acute spinal cord ischaemia. Neuroradiology. 2003;45:557-561.
115. Shinoyama M, Takahashi T, Shimizu H, Tominaga T, Suzuki M. Spinal cord infarction demonstrated by diffusion-weighted magnetic resonance imaging. J Clin Neurosci. 2005;12:466-468.
116. Thron A. [Spinal dural arteriovenous fistulas]. Radiologe. 2001;41: 955-960.
117. Koenig E, Thron A, Schrader V, Dichgans J. Spinal arteriovenous malformations and fistulae: clinical, neuroradiological and neurophysiological findings. J Neurol. 1989;236:260-266.
118. Saraf-Lavi E, Bowen BC, Quencer RM, et al. Detection of spinal dural arteriovenous fistulae with MR imaging and contrast-enhanced MR angiography: sensitivity, specificity, and prediction of vertebral level. AJNR Am J Neuroradiol. 2002;23:858-867.
119. Krings T, Mull M, Reinges MH, Thron A. Double spinal dural arteriovenous fistulas: case report and review of the literature. Neuroradiology. 2004;46:238-242.
120. Behrens S, Thron A. Long-term follow-up and outcome in patients treated for spinal dural arteriovenous fistula. J Neurol. 1999;246:181-185.
121. Tobias ME, McGirt MJ, Chaichana KL, et al. Surgical management of long intramedullary spinal cord tumors. Childs Nerv Syst. 2008;24: 219-223.
122. Harrop JS, Ganju A, Groff M, Bilsky M. Primary intramedullary tumors of the spinal cord. Spine (Phila Pa 1976). 2009;34:S69-S77.
123. Grimm S, Chamberlain MC. Adult primary spinal cord tumors. Expert Rev Neurother. 2009;9:1487-1495.
124. Dropcho EJ. Neurotoxicity of radiation therapy. Neurol Clin. 2010;28: 217-234.
125. Melki PS, Halimi P, Wibault P, Masnou P, Doyon D. MRI in chronic progressive radiation myelopathy. J Comput Assist Tomogr. 1994;18:1-6.